Malaria medicines: a glass half full?

22 May 2015

Timothy N. C. Wells, Rob Hooft van Huijsduijnen and Wesley C. Van Voorhis

Nature Reviews Drug Discovery

DOI: 10.1038/nrd4573

Photo: Michael Nivelet/


Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. In this Review, we discuss how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.

Read the full article on the Nature website.